35 results found | searching for "consumables"
-
-
Global Single Use Bioprocessing Market Worth $34.9 Billion by 2029: Key Insights and Analysis https://www.marketsandmarkets.com/Market-Reports/single-use-bioprocessing-market-231651297.html The single-use bioprocessing market is expected to grow at a CAGR of 14.5% during the forecast period. The market is estimated to be around USD 17.7 billion in 2024 and is projected to reach USD 34.9 billion by 2029. Growing biologics & biosimilars market, need for low capital investment, a surge in single-use bioprocessing adoption among CDMOs & CMOs, and advantages such as increased productivity & reduced risk of cross contamination, are some factors responsible for the growth of the market. On the other hand, issues related to leachables & extractables, regulatory compliance, and discussions about PFAS restrictions are hampering the market growth. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297 Based on products, the single-use bioprocessing market is segmented into equipment and consumables. The consumables segment accounted for the largest share and is also estimated to grow at the highest CAGR of the single-use bioprocessing market. This can be attributed to their repeated purchase, higher usage, frequent replacement, and broad application range. Based on application, the single-use bioprocessing market is segmented into cell culture, filtration, purification, mixing, storage & transfer, and other applications. The filtration segment accounted for the largest share of the single-use bioprocessing market. The large share of this segment can be attributed to the wide use of equipment for various filtration applications in the pharmaceutical industry, increased filtration requirements in the biopharmaceutical industry, and the higher requirement for these filters compared to consumables and filtration accessories. Based on workflow, the single-use bioprocessing market is segmented into upstream and downstream bioprocessing. The growth of the single-use bioprocessing market for upstream bioprocesses is driven by technological advancements and strategic collaborations between industry players. For instance, in June 2023, Culture Biosciences and Cytiva collaborated to introduce new bioprocess solutions that leverage digitization, in-silico approaches, and virtual monitoring and control of experiments. This collaboration revolutionized upstream processing by providing customers unprecedented access to cutting-edge technologies and methodologies, fueling the demand for advanced bioprocessing solutions. Based on molecule type, the single-use bioprocessing market is segmented into monoclonal antibodies (mAbs), vaccines, therapeutic proteins & peptides, and cell & gene therapies. mAbs accounted for the largest share of the single-use bioprocessing market. The large share is attributed to the increasing pharmaceutical R&D drug pipeline, increasing incidence of cancer, and rising usage & demand for cancer therapy. Based on the end user, the single-use bioprocessing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and CMOs & CROs. In 2023, pharmaceutical & biotechnology companies accounted for the largest share of the single-use bioprocessing market due to their higher adoption of single-use bioprocessing equipment and consumables, the stringent regulatory scenario, increased R&D activities, increased production of biologics, and rising manufacturing of biologics and biosimilars in developed countries. Based on region, single-use bioprocessing market is segmented into six major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the single-use bioprocessing market. Europe held the second largest share followed by the Asia Pacific. The Asia Pacific market is expected to show the highest growth rate during the forecast period. Growing pharmaceutical R&D activities, increasing demand for biosimilars, significant investments by biopharmaceutical companies & CMOs in emerging Asia Pacific countries, are some of the factors contributing to the regional growth. Key players in the single-use bioprocessing market include Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Avantor, Inc. (US), 3M Company (US), Repligen Corporation (US), Entegris (US), Getinge AB (Sweden), Parker Hannifin Corporation (US), Alfa Laval Corporate AB (Sweden), Saint-Gobain (France), Eppendorf SE (Germany), Corning Incorporated (US), Eaton Corporation plc (Ireland)v, METTLER TOLEDO (US), Porvair PLC (UK), Lonza (Switzerland), ABEC, INC. (US), NewAge Industries (US), PBS Biotech, Inc. (US), Sentinel Process Systems, Inc. (US), Meissner Filtration Products, Inc. (US), SATAKE MultiMix Corporation (Japan), Hamilton Company (US), Membrane Solutions (US), Cole-Parmer Instrument Company, LLC (US), Distek, Inc. (US), Esco Lifesciences Group Ltd. (US), and TECNIC Bioprocess solutions (Spain). Recent Developments of the Single Use Bioprocessing Industry: In April 2024, Cytiva introduced the Xcellerex magnetic mixer, a single-use mixing system in 2,000 and 3,000 L capacities for large-scale mAb, vaccine, and genomic medicine manufacturing processes. In April 2023, Merck KGaA launched the Ultimus single-use process container film designed to provide extreme durability and leak resistance for single-use assemblies used for bioprocessing liquid applications. -
-
Global Enteral Feeding Devices Market Worth $5.6 Billion by 2029: Key Insights and Analysis https://www.marketsandmarkets.com/Market-Reports/enteral-feeding-device-market-183623035.html The global enteral feeding devices market is projected to reach 5.6 billion in 2029 from USD 4.0 billion in 2023, at a CAGR of 6.2% between 2023 and 2029. The rising technological advancemnets and increasing geriatric population is driving the growth of the market. The As the global population ages, the number of individuals requiring enteral feeding is expected to rise. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=183623035 Elderly patients often experience age-related decline in appetite or swallowing difficulties, making enteral feeding a vital support system. Based on type, the enteral feeding devices market is segmented into enteral feeding tubes, enteral feeding pumps, administration sets, enteral syringes and consumables. The enteral feeding tubes accounts for the largest share in the enteral feeding devices market, Enteral feeding tubes are a crucial component of enteral feeding devices. They act as a conduit to deliver liquid nutrition directly into a patient's stomach or small intestine, bypassing the mouth and esophagus. Enteral feeding tubes are essential components of enteral feeding devices, providing a safe and reliable way to deliver essential nutrients to patients who cannot consume food orally which is expected to drive the segment growth. Based on application, the enteral feeding devices market is segmented into oncology, gastrointestinal diseases, nuerological diseases, diabetes, hypermetabolism and other applications. The oncology accounts for the largest share in the enteral feeding devices market, cancer and its treatment (surgery, radiation, chemotherapy) can significantly impact a patient's appetite and ability to absorb nutrients. Enteral feeding ensures they receive the necessary calories, proteins, vitamins, and minerals to support their immune system, fight infection, and promote healing which is expected to drive the market growth. In 2023, North America accounted for the largest share of the enteral feeding devices market, followed by Europe and Asia Pacific. The United States and Canada have well-equipped hospitals and a strong focus on advanced medical care, which supports the adoption of enteral feeding devices, also compared to established markets like North America and Europe, the Asia Pacific region often offers lower labor costs, making it an attractive option for companies seeking to optimize manufacturing expenses. Additionally, several countries in the region, like China and India, have developed a robust infrastructure for manufacturing pharmaceuticals and medical devices which is expected to lead to Asia Pacific growing at the fastest rate during the forecast period. The major players in the enteral feeding devices market include include The prominent players in the medical device contract manufacturing market include Fresenius SE & Co. KGAA (Germany), Cardinal Health, Inc. (US), Nestlé S.A. (Switzerland), Avanos Medical, Inc. (US), Danone S.A. (France), Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), CONMED Corporation (US), Cook Medical (US), Moog Inc. (US), Boston Scientific Corporation (US), Baxter International Inc. (US), Vygon (France), and Other players in the enteral feeding devices market are Applied Medical Technology (US), Amsino International Inc. (US), Omex Medical Technology (India), Danumed Medizintechnik (Germany), Medline Industries, Inc. (US), Fuji Systems (Japan), Kentec Medical (US), Dynarex Corporation (US), Vesco Medical LLC (US), Medela AG (Switzerland), Alcor Scientific (US), and Romsons (India) Recent Developments of Enteral Feeding Devices Industry: In September 2022, Cardinal Health, Inc. (US) announced the partnership with Kinaxis (Canada) to enhance the Kinaxis RapidResponse Platform used for supply chain agility and medical product visibility. In November 2022, Boston Scientific signed an agreement for the acquisition of Apollo Endosurgery, Inc.,. This agreement includes devices, which are used during endoluminal surgery (ELS) procedures, to close gastrointestinal defects, manage gastrointestinal complications, and aid in weight loss for patients suffering from obesity. In March 2021, Applied Medical Technology, Inc. (US) launched its gastric-jejunal enteral feeding tube family (G-JETs) to include the low-profile micro-G-JET to link up the enteral nutrition needs of pediatric patients. In March 2022, Vygon Group (France) announced the acquisition of distributor Macatt Medica (Peru). The acquisition is expected to grow the presence of Vygon Group (France), in the South American region, specifically for its broad range of enteral feeding products. -
-
Exploring the $6.3 Billion Autoimmune Disease Diagnosis Market: Trends and Growth Drivers https://www.marketsandmarkets.com/Market-Reports/autoimmune-disease-diagnosis-market-174826519.html The report "Autoimmune Disease Diagnosis Market by Product (Consumables, Assay Kits, Instruments), Test Type (Inflammatory Markers, Routine Laboratory Tests), Disease (RA, SLE, Thyroiditis, Scleroderma), End User (Hospitals, Clinical Labs) - Global Forecast to 2025" The global autoimmune disease diagnosis market size is projected to reach USD 6.3 billion by 2025 from USD 4.1 billion in 2020, growing at a CAGR of 8.9% from 2020 to 2025. Factors driving the growth of this market include high incidence and large economic burden of autoimmune diseases, increasing healthcare expenditure, and growing access to medical insurance in the US. Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownload.asp?id=174826519 By product and service, the Autoimmune Disease Diagnosis Market is classified into consumables & assay kits, instruments and services. The consumables & assay kits segment is expected to lead the global autoimmune disease diagnosis in 2017. Factors driving the growth of this segment include increasing adoption of consumables in hospitals and clinical laboratories, rising incidence of autoimmune diseases, and increasing demand for quick results. On the basis of test type, the Autoimmune Disease Diagnosis Market is categorized into routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and other tests. In 2017, the routine laboratory tests segment is estimated to account for the largest share of the global Autoimmune Disease Diagnosis Market. The increasing incidence autoimmune diseases, along with increasing adoption of routine laboratory tests for a variety of diseases are the key factors driving the growth of this end-user segment. By disease, the market is segmented into systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, thyroiditis, scleroderma, and other diseases. The rheumatoid disease segment is expected to account for the largest share of the global autoimmune disease diagnosis in 2017. The growth of this segment is mainly driven by the increasing incidences of the disease. On the basis of end user, the Autoimmune Disease Diagnosis Market is categorized into clinical laboratories, hospitals, and other end users. The clinical laboratories segment is estimated to account for the largest share of the global Autoimmune Disease Diagnosis Market during the forecast period. The heavy burden of autoimmune diseases, along with the accessibility and availability of diagnosis and treatment instruments in clinical laboratories in a short period of time are the key factors driving the growth of this end-user segment. Based on region, the Autoimmune Disease Diagnosis Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the Autoimmune Disease Diagnosis Market in 2017. This is attributed to factors such as accessibility to advanced technologies and opportunities for advanced autoimmune diagnostic testing and screening, growing incidence of autoimmune diseases, and technological advancements of autoimmune disease diagnosis in the region as compared to other regions. Key players in the Autoimmune Disease Diagnosis Market include Thermo Fisher Scientific. (US), Danaher (US), HYCOR Biomedical (US), Siemens (Germany), Bio-Rad Laboratories. (US), and Abbott (US). -
-
How to Choose the Best Sticker Printer Machine for Your Needs Choosing the best sticker printer machine involves evaluating several key factors to match your specific needs. First, consider the type of stickers you plan to print—whether they're for personal use or professional production. Look for a machine that offers high resolution and color accuracy to ensure vibrant, detailed prints. Check the machine’s compatibility with different sticker materials and sizes to ensure versatility. Evaluate the ease of use and setup, especially if you're new to sticker printing. Additionally, consider the cost of consumables and maintenance to gauge the overall value. A good sticker printer machine should balance quality, functionality, and cost-effectiveness, allowing you to produce excellent stickers efficiently. Buy link: - https://cricutindiastore.com/product/cricut-joy-machine/
-
-
Bio Decontamination Market Anticipated to Reach $339 Million by 2028 https://www.marketsandmarkets.com/Market-Reports/bio-decontamination-market-104696777.html The global Bio Decontamination market is projected to reach USD 339 million by 2028 from USD 238 million in 2023, at a CAGR of 7.3% during the forecast period. The growth of this market is majorly driven by Increased outsourcing of bio decontamination services and Rising growth in pharmaceutical & biotechnology industries. However, the Rising adoption of single-use medical devices may restrain the growth of this market. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=104696777 Based on Product & Service, the Bio Decontamination Market is segmented into Consumables, Equipment, & Services. The Services segment is projected to grow at the highest CAGR during the forecast period. The major factors contributing to the growth of this market are: The services segment is growing mainly due to its low cost (as compared to the costs incurred while setting up in-house decontamination facilities, buying equipment, allotting storage space, and in repair & maintenance). Based on the Agent type, the Bio Decontamination Market is segmented into Hydrogen Peroxide, Chlorine Dioxide, Peracetic Acid, Nitrogen Dioxide, The Hydrogen Peroxide segment is expected to dominate the market during the forecast period due Vaporized hydrogen peroxide is one of the commonly used bio decontamination agents moreover it has wide application areas, including pharmaceutical & medical device manufacturing, biosciences & biotechnology research labs, hospitals & healthcare facilities, and veterinary applications. Several regulations also support the use of hydrogen peroxide, such as the US EPA. Based on the Type, the Bio Decontamination Market is segmented into Chamber Decontamination, Room Decontamination. The Chamber Decontamination segment is expected to dominate the market during the forecast period because the power consumption of bio decontamination chambers is less than room decontamination. It is also less costly, which has stimulated the adoption of chamber bio decontamination. Based on the end user, the Bio Decontamination Market is segmented into Pharmaceutical & Medical Device Manufacturing Companies, Life Sciences & Biotechnology Research Organizations, Hospitals & Healthcare Facilities. The Pharmaceutical & Medical Device Manufacturing Companies is expected to dominate the market during the forecast period due to Bio decontamination is an integral part of the pharmaceutical manufacturing process. Pharmaceutical manufacturing companies are facing increased pressure to ensure the integrity of their products and maintain manufacturing facilities that are free from contamination of any kind. Failure to maintain good manufacturing practices (GMP) has resulted in severe consequences. Similarly, medical device manufacturing companies also must follow strict guidelines to prevent and control medical devices from being contaminated at their facilities. Based on the region, the Bio Decontamination Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2022, North America accounted for the largest share of the Bio Decontamination Market. Growth in the North American market is mainly driven by the growing demand for bio decontamination technologies from the healthcare industry to minimize the occurrence of hospital-acquired infections (HAIs) and the increasing presence of major manufacturers in the region. The significant players in the Bio Decontamination market are Steris PLC (US), Ecolab (US), TOMI Environmental Solutions, Inc (US), JCE Biotechnology (France), Fedegari Autoclavi SpA (Italy), Zhejiang TAILIN Bioengineering Co., LTD (China), Howorth Air Technology Ltd. (UK), Solidfog Technologies (Belgium), ClorDiSys (US), Amira (Italy) Recent Developments In July 22, Ecolab’s (US) Bioquell HPV-AQ received an authorized approval for use in all territories of the European Union and the European Economic Area. In Dec 2022, the TOMI Environmental Solutions, Inc (US) launched new SteraMist products, which include the Select Plus-a hybrid product consisting of the Company’s current Surface Select and Environment systems. (The system is 24 volts, allowing for universal outlet usage and convert more of the hydrogen peroxide BIT Solution to hydroxyl radicals thus lowering H2O2 PPM levels allowing for faster turnaround time). -
-
Market Surge: Multiplex Assays Expected to Hit $5.3 Billion https://www.marketsandmarkets.com/Market-Reports/multiplex-assays-market-61593314.html The multiplex assays market is valued at an estimated USD 3.5 billion in 2022 and is projected to reach USD 5.3 billion by 2027, at a CAGR of 8.8% during the forecast period. The increasing applications of companion diagnostics in drug development and the significance of multiplex assays in companion diagnostics are expected to drive the multiplex assays market. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=61593314 Based on product & service, the multiplex assays market is segmented into three broad categories, namely, consumables, instruments, and software & services. In 2022, the consumables segment accounted for the largest share of the market. The availability of a wide range of reagents and kits and increasing use of assays in different oncology therapeutic treatments are some of the major factors driving the growth of the consumables market. On the basis of type, the multiplex assays market is segmented into protein, nucleic acid, and cell-based multiplex assays. The nucleic acid multiplex assays segment is further divided into planar, bead-based, and other nucleic acid multiplex assays. The protein multiplex assays segment is further categorized into planar, bead-based, and other protein multiplex assays. The protein multiplex assays segment accounted for the largest share of the global multiplex assays market in 2022. Protein multiplex assays are preferred over traditional protein analysis tools mainly due to their distinct advantages, such as the simultaneous profiling of multiple analytes using smaller sample amounts. Such distinct features make protein multiplex assays more suitable for research applications where samples are scarce and valuable resources. This is expected to support market growth of this segment. Based on technology, the multiplex assays market is divided into flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies. In 2022, the flow cytometry segment accounted for the largest share of the global multiplex assays market. Its wide applications in protein expression, RNA, and cell health status makes it the largest market segment. Based on applications, the multiplex assays market is segmented into research & development (drug discovery & development and biomarker discovery & validation) and clinical diagnostics (infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism & endocrinology disorders, and other diseases). The research & development application segment is expected to account for the largest share of the multiplex assays market in 2022. Multiplex assays are easy to use and are associated with reduced turnaround times, owing to which they are preferred for research & development applications as compared to conventional single plex assays. The global multiplex assays market has been segmented into five major regions— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). In 2022, North America accounted for the largest share of the global multiplex assays market. The large share of North America in the global market is attributed to factors such as the rising amount of government funding for R&D in multiplex assays; an increasing number of seminars and workshops about emerging technologies in the domain of multiplex assays; the growing adoption of companion diagnostics for personalized treatment; and the rising need for effective analytical platforms to reduce operational costs. Major Companies: Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), QIAGEN N.V. (Netherlands), Abcam plc (UK), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Quanterix (US), Bio-Techne (US), MESO SCALE DIAGNOSTICS, LLC (US), Randox Laboratories Ltd. (UK), Olink (Sweden), Seegene Inc. (South Korea), Siemens Healthcare AG (Germany), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Promega Corporation (US), Enzo Biochem Inc. (US), Cayman Chemical (US), Boster Biological Technology (US), Antigenix America, Inc. (US), Quansys Biosciences Inc. (US), and RayBiotech Life, Inc. (US). Recent Developments In September 2021, Bio-Rad Laboratories launched its Bio-Plex Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The panels are for research use only (RUO). In September, DiaSorin S.p.A. received the CE mark approval for its Simplexa COVID-19 & Flu A/B Direct kit, a multiplex test for the in vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus, and influenza B virus from the same patient sample in one reaction well. The assay is designed for use on the LIAISON MDX and is run directly from nasopharyngeal swabs (NPS) without the need for offboard extraction. In August 2021, Becton, Dickinson and Company launched its new and fully automated high-throughput diagnostic system, BD COR System. The system uses robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the US. In July 2021, DiaSorin S.p.A. acquired the leading company of multiplex assays, Luminex Corporation, for a price of USD 37.00 per share, that corresponds to a total equity value of approximately USD 1.8 billion. In February 2021, Thermo Fisher Scientific acquired Mesa Biotech, a privately-held point-of-care molecular diagnostic company. This acquisition strengthened Thermo Fisher's operational excellence, access to raw materials, and existing distribution & sales channels with Mesa's innovative platform with a diverse array of diagnostic products, such as Accula System by Mesa Biotech that is dedicated to COVID-19 testing. -
-
Autoimmune Disease Market Size, Share & Segmentation By Product (Consumables and Assay Kits Instruments ),By Test type (Laboratory Tests, Inflammatory Markers Autoantibodies & Immunologic tests ), By Disease Type(Systematic Autoimmune Disease, Localize Autoimmune Disease) By End User (Clinical Laboratories, Hospitals) https://www.linkedin.com/pulse/autoimmune-disease-market-size-unleashing-growth-outlook-deshmukh-hnq5f/
-
-
https://www.precisionbusinessinsights.com/market-reports/chromatography-consumables-market The global chromatography consumables market size was valued at USD 4,844.6 million in 2023 and is poised to grow at a significant CAGR of 7.2% during the forecast period 2024-30. It also includes market size and projection estimations for each of the five major regions from 2024 to 2030. The research report includes historical data, trending features, and market growth estimates for the future. -
-
World of Warcraft Classic Season of Discovery Gold World of Warcraft Season of Discovery Gold is the primary in-game currency, enabling players to purchase essential equipment and consumables. Its value is influenced by the game's economy and the needs of its player community. Gold farming involves collecting valuable resources through Gathering professions such as Herbalism and Mining, or by selling rare loot drops. Other profitable activities include Auction House flipping and rare mob and elemental farming. Better is to click here or visit our official website https://www.mmogah.com/wow-classic-season-of-discovery-gold to know about wow sod gold.
-
-
Affordable Copier Machine Rental in Singapore We cover certain things in the contract of our copier machine rental such as all consumables, all toners, free telephone support, all spare parts, priority response, unlimited calls & labor, and a free loan copier. visit our website: - https://copierpc.com.sg/
Copyright 2019 © P-tweets Refunds